Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 160

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Estimated morbidity and mortality in adolescents and young adults diagnosed with Type 2 diabetes mellitus

Open access
Rhodes, E. T., Prosser, L. A., Hoerger, T. J., Lieu, T., Ludwig, D. S., Laffel, L. M. · 2012 · Diabetic Medicine

Abstract

Diabet. Med. 29, 453–463 (2012) Aims To estimate remaining life expectancy (RLE), quality‐adjusted life expectancy (QALE), causes of death and lifetime cumulative incidence of microvascular/macrovascular complications of diabetes for youths diagnosed with Type 2 diabetes. Methods A Markov‐like computer model simulated the life course for a hypothetical cohort of adolescents/young adults in the USA, aged 15–24 years, newly diagnosed with Type 2 diabetes following either conventional or intensive treatment based on the UK Prospective Diabetes Study. Outcomes included RLE, discounted QALE in quality‐adjusted life years (QALYs), cumulative incidence of microvascular/macrovascular complications and causes of death. Results Compared with a mean RLE of 58.6 years for a 20‐year‐old in the USA without diabetes, conventional treatment produced an average RLE of 43.09 years and 22.44 discounted QALYs. Intensive treatment afforded an incremental 0.98 years and 0.44 discounted QALYs. Intensive treatment led to lower lifetime cumulative incidence of all microvascular complications and lower mortality from microvascular complications (e.g. end‐stage renal disease (ESRD) death 19.4% vs. 25.2%). Approximately 5% with both treatments had ESRD within 25 years. Lifetime cumulative incidence of coronary heart disease (CHD) increased with longer RLE and greater severity of CHD risk factors. Incorporating disutility (loss in health‐related quality of life) of intensive treatment resulted in net loss of QALYs. Conclusions Adolescents/young adults with Type 2 diabetes lose approximately 15 years from average RLE and may experience severe, chronic complications of Type 2 diabetes by their 40s. The net clinical benefit of intensive treatment may be sensitive to preferences for treatment. A comprehensive management plan that includes early and aggressive control of cardiovascular risk factors is likely needed to reduce lifetime risk of CHD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1464-5491.2011.03542.x

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 160

Metadata

Authors
Rhodes, E. T., Prosser, L. A., Hoerger, T. J., Lieu, T., Ludwig, D. S., & Laffel, L. M.
Venue
Diabetic Medicine
Publisher
Wiley
Published
2012-03-12
Volume
29
Issue
4
Pages
453-463
ISSN
  • 0742-3071 (ISSN-L)
  • 1464-5491
OpenAlex
W1923719155
Cited by
160
References
10
FWCI
8.00
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Estimated morbidity and mortality in adolescents and young adults diagnosed with Type 2 diabetes mellitus. https://app.cochat.ai/papers/10.1111/j.1464-5491.2011.03542.x
The paper
Rhodes, E. T., Prosser, L. A., Hoerger, T. J., Lieu, T., Ludwig, D. S., & Laffel, L. M. (2012). Estimated morbidity and mortality in adolescents and young adults diagnosed with Type 2 diabetes mellitus. Diabetic Medicine. https://doi.org/10.1111/j.1464-5491.2011.03542.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.